Generic Name and Formulations:
Bupivacaine 13.3mg/mL; liposome injectable suspension; preservative-free.
Pacira Pharmaceuticals, Inc.
Indications for EXPAREL:
For administration into the surgical site to produce postsurgical analgesia.
For single-dose administration only. Base dose on surgical site and volume required to cover area. Inject slowly into soft tissue via infiltration. Bunionectomy: 106mg (volume: 8mL). Hemorrhoidectomy: 266mg (volume: 20mL). See full labeling for administration.
<18yrs: not established.
Local anesthetic (amide-type).
Obstetrical paracervical block.
Not interchangeable with other forms of bupivacaine. Avoid intravascular, intra-articular, intrathecal, epidural, or regional nerve block inj. To be administered under the supervision of experienced clinicians. Cardiovascular disease. Hepatic or renal impairment. Monitor cardiovascular and respiratory vital signs. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Do not dilute with water or hypotonic agents (may result in disruption of liposomal particles). Do not mix with lidocaine or other non-bupivacaine-based local anesthetics. Do not administer other forms of bupivacaine within 96hrs following administration of Exparel. May administer after at least 20 mins following local administration of lidocaine. Bupivacaine HCl, when injected immediately before or admixed with Exparel, may impact the pharmacokinetic and/or physicochemical properties of the drugs.
Nausea, constipation, vomiting, pyrexia, dizziness, edema peripheral, anemia, hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain; CNS effects (eg, excitation, depression, restlessness, anxiety, tremors), cardiovascular effects (eg, decreased cardiac output, AV block, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, paresthesia, weakness, paralysis of lower extremities).
Single-use vial (20mL)—10